Frazier Management LLC Krystal Biotech, Inc. Transaction History

Frazier Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$51.99 - $72.11 $40.1 Million - $55.6 Million	-771,250 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$52.01 - $71.77 $864,718 - $1.19 Million	-16,626 Reduced 2.11%	771,250 $40.3 Million
Q2 2021 Aug 11, 2021	SELL	$62.14 - $81.82 $6.66 Million - $8.76 Million	-107,124 Reduced 11.97%	787,876 $53.6 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $544,000 - $824,000	20,000 Added 2.29%	895,000 $36 Million
Q4 2018 Feb 11, 2019	BUY	$15.03 - $25.38 $3.76 Million - $6.35 Million	250,000 Added 40.0%	875,000 $18.2 Million
Q3 2018 Nov 14, 2018	BUY	$14.43 - $21.0 $9.02 Million - $13.1 Million	625,000 New	625,000 $11 Million

275

24.9M

270K

172K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.54B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

Stay updated on Frazier Management LLC with notifications on news.